DC
Publicaties op Oncologisch.com
Final totale overleving and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of an...
Prospective gerandomiseerde phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal ce...
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year...
Enfortumab vedotin versus chemotherapie bij urotheelcarcinoom: EV-301 24-maanden
Sunitinib bij pancreatische neuro-endocriene tumoren: geactualiseerde PFS en definitieve overleving